SOGROYA (Novo Nordisk Pharmaceuticals Pty Ltd)
Product name
SOGROYA
Date registered
Evaluation commenced
Decision date
Approval time
133 (255 working days)
Active ingredients
somapacitan
Registration type
NCE/NBE
Indication
SOGROYA (solution for injection) is indicated for the replacement of endogenous growth hormone (GH) in adults with growth hormone deficiency (AGHD).